Compounds > m antigen, brucella melitensis

Page last updated: 2024-11-11

m antigen, brucella melitensis

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

M antigen, Brucella melitensis: preparation of soluble antigen of Brucella melitensis; Brucella melitensis M antigen [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	5488723
MeSH ID	M0127819

Synonyms (10)

Synonym
brucella melitensis m antigen
4h-1-benzopyran-4-one, 7-((6-deoxy-3-o-(6-deoxy-alpha-l-mannopyranosyl)-alpha-l-mannopyranosyl)oxy)-3-((6-o-beta-d-galactopyranosyl-beta-d-glucopyranosyl)oxy)-5-hydroxy-2-(4-hydroxyphenyl)-
melitin
m antigen (brucella melitensis)
melitine
m antigen, brucella melitensis
7-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one
81944-31-2
DTXSID601002332
3-[(6-o-hexopyranosylhexopyranosyl)oxy]-5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-4h-1-benzopyran-7-yl 6-deoxy-3-o-(6-deoxyhexopyranosyl)hexopyranoside

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	10 (62.50)	18.7374
1990's	2 (12.50)	18.2507
2000's	1 (6.25)	29.6817
2010's	3 (18.75)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	11.82 (24.57)
Research Supply Index	2.94 (2.92)
Research Growth Index	4.76 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (11.82)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (11.11%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	16 (88.89%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
1,2-dipalmitoylphosphatidylcholine 1,2-Dipalmitoylphosphatidylcholine: Synthetic phospholipid used in liposomes and lipid bilayers to study biological membranes. It is also a major constituent of PULMONARY SURFACTANTS.	1.98	1	0
acrylic acid acrylic acid: RN given refers to parent cpd. acrylic acid : A alpha,beta-unsaturated monocarboxylic acid that is ethene substituted by a carboxy group.	2.11	1	0	alpha,beta-unsaturated monocarboxylic acid	metabolite
tert-butylacrylamide tert-butylacrylamide: structure in first source	2.11	1	0
n,n'-methylenebisacrylamide [no description available]	2.11	1	0
n-isopropylacrylamide N-isopropylacrylamide: can polymerize with glycidyl acrylate to form reactive water-soluble polymer that can react with the amino groups of enzymes-proteins or other ligands	2.11	1	0
organophosphonates hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.	2.02	1	0	divalent inorganic anion; phosphite ion
6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2h-pyran-2-one 6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one: structure given in first source; potent irreversible, mechanism-based inhibitor of myocardial calcium-independent phospholipase A2	2.02	1	0	naphthalenes

Condition	Indicated	Relationship Strength	Studies	Trials
Brucella Infection [description not available]	0	3.45	8	0
Brucellosis Infection caused by bacteria of the genus BRUCELLA mainly involving the MONONUCLEAR PHAGOCYTE SYSTEM. This condition is characterized by fever, weakness, malaise, and weight loss.	0	3.45	8	0
Eosinophilia, Tropical [description not available]	0	1.94	1	0
Allergic Reaction [description not available]	0	2.62	3	0
Leukocyte Disorders Disordered formation of various types of leukocytes or an abnormal accumulation or deficiency of these cells.	0	1.94	1	0
Disease, Pulmonary [description not available]	0	1.94	1	0
Eosinophilia Abnormal increase of EOSINOPHILS in the blood, tissues or organs.	0	1.94	1	0
Hypersensitivity Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.	0	2.62	3	0
Lung Diseases Pathological processes involving any part of the LUNG.	0	1.94	1	0
Diseases of Immune System [description not available]	0	1.93	1	0
Immune System Diseases Disorders caused by abnormal or absent immunologic mechanisms, whether humoral, cell-mediated, or both.	0	1.93	1	0
Nerve Degeneration Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.	0	2.02	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	0	2.02	1	0
Bacterial Endocarditides [description not available]	0	1.96	1	0
Endocarditis, Bacterial Inflammation of the ENDOCARDIUM caused by BACTERIA that entered the bloodstream. The strains of bacteria vary with predisposing factors, such as CONGENITAL HEART DEFECTS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; or intravenous drug use.	0	1.96	1	0